Drug intelligence / Profile preview

AP026

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

AP026 is a recombinant fusion protein being developed by Chia Tai Tianqing Pharmaceutical Group and Sino Biopharmaceutical. It is designed to modulate fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 (GLP-1) pathways. The drug is currently in Phase I clinical trials for the treatment of type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Targets

GLP1R (GLP-1R)FGF21 (Fibroblast growth factor 21)

Beyond the preview

Go deeper on AP026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP026.

Explore the full profile